|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-3.42/-2.11
|
Enterprise Value
9.37M
|
Balance Sheet |
Book Value Per Share
1.70
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
145.80K
|
Operating Revenue Per Share
0.02
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 01:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |